NCT03009201 - Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

October 8, 2019

Study Completion Date

June 30, 2023

Conditions

Advanced Soft Tissue SarcomaLocally Advanced AngiosarcomaLocally Advanced LeiomyosarcomaLocally Advanced LiposarcomaLocally Advanced Malignant Peripheral Nerve Sheath TumorLocally Advanced MyxofibrosarcomaLocally Advanced Undifferentiated Pleomorphic SarcomaMetastatic AngiosarcomaMetastatic Epithelioid SarcomaMetastatic FibrosarcomaMetastatic LiposarcomaMetastatic Malignant Peripheral Nerve Sheath TumorMetastatic MyxofibrosarcomaMetastatic Soft Tissue SarcomaMetastatic Synovial SarcomaMetastatic Undifferentiated Pleomorphic SarcomaMyxofibrosarcomaPleomorphic RhabdomyosarcomaStage III Soft Tissue Sarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Undifferentiated (Embryonal) SarcomaUnresectable LeiomyosarcomaUnresectable LiposarcomaUnresectable Malignant Peripheral Nerve Sheath TumorUnresectable Soft Tissue SarcomaUnresectable Synovial SarcomaUnresectable Undifferentiated Pleomorphic Sarcoma

Interventions

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ribociclib

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland